Specifically, an analysis of both stable CAD [85] and ACS [51] patients showed no effect of PCSK9 inhibition in highly sensitive C-reactive protein (hs-CRP), with a meta-analysis also confirming these findings [86]. Here, PCSK9 is linked to coronary artery disorder.